Is Egrifta (Tesamorelin) Legal in Ohio?

Federal Legal Status of Tesamorelin

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). The FDA approved it in November 2010 under the brand name Egrifta for reducing excess visceral abdominal fat in HIV-positive adults with lipodystrophy, and again in 2019 under the Egrifta SV formulation. [1] Because it holds full FDA approval, it sits in a fundamentally different legal category than unapproved research peptides.

Controlled-Substance Status

Tesamorelin does not appear in any schedule of the Controlled Substances Act. [2] The Drug Enforcement Administration (DEA) has not placed it in Schedules I through V. This means a DEA registration number on a prescription is not required, and there are no federal quantity limits comparable to those governing testosterone or benzodiazepines.

FDA Approval vs. Off-Label Use

The approved label covers a narrow indication: HIV-associated lipodystrophy in adults. Off-label prescribing, however, is legal under federal law. The FDA does not regulate the practice of medicine, so a licensed Ohio clinician may prescribe tesamorelin for other purposes supported by clinical evidence, such as age-related changes in body composition or cognitive investigations, as long as the prescriber can document medical necessity.

Where Tesamorelin Falls on the Peptide Spectrum

The FDA maintains a "Bulk Drug Substances" list under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Substances placed on the 503A Category 2 list are nominally disfavored for compounding because an FDA-approved version already exists. [3] Tesamorelin is subject to this tension: Egrifta SV is commercially available, which complicates (but does not prohibit) compounding, as outlined below.

Ohio State Legal Framework

Ohio has no statute or administrative rule that specifically restricts, bans, or schedules tesamorelin beyond what federal law requires. The Ohio Revised Code (ORC) and the Ohio Administrative Code (OAC) defer to federal scheduling for controlled substances, and because tesamorelin is not federally scheduled, it receives no additional Ohio classification.

Ohio State Board of Pharmacy

The Ohio State Board of Pharmacy regulates the dispensing of all legend drugs, including tesamorelin. Any pharmacy filling an Egrifta prescription must be licensed with the Board, maintain proper cold-chain handling (tesamorelin requires refrigeration at 2°C to 8°C), and verify a valid, current prescription. The Board's rules do not single out tesamorelin for heightened scrutiny. [4]

Ohio Medical Practice Act

Under ORC Chapter 4731, a licensed Ohio physician (MD or DO) may prescribe tesamorelin within the scope of their practice. Certified nurse practitioners and physician assistants with appropriate prescriptive authority may also prescribe it under Ohio law. The prescriber must conduct a good-faith evaluation, document the clinical rationale, and follow standard-of-care documentation for any prescription.

Telehealth Prescribing in Ohio

Ohio's telehealth statute (ORC 4743.09, effective 2023) allows prescribers to issue prescriptions following a synchronous audio-visual encounter, provided they establish a valid patient-provider relationship. This means an Ohio resident may lawfully receive a tesamorelin prescription from a telehealth platform without an in-person visit, as long as the prescriber holds an active Ohio license or practices under reciprocal licensure.

Compounding Tesamorelin in Ohio: 503A vs. 503B Rules

Compounding is the primary route through which patients receive tesamorelin outside the brand-name Egrifta SV product, particularly when the commercially available product is on backorder or a patient requires a dose form not commercially available (for example, a different concentration or a multi-dose vial).

503A Compounding Pharmacies

Section 503A of the FD&C Act governs traditional compounding pharmacies that prepare patient-specific prescriptions. These pharmacies may compound tesamorelin only when:

1. A valid, patient-specific prescription exists.
2. The compounded product is not essentially a copy of a commercially available drug.
3. The pharmacy is licensed in Ohio (or ships into Ohio from a licensed out-of-state facility under interstate pharmacy rules).

The "essentially a copy" restriction is where legal complexity arises. Because Egrifta SV is available commercially, a 503A pharmacy must demonstrate a clinical difference (for instance, a different strength, a preservative-free formulation for a patient with documented allergy, or a delivery route the brand does not offer) to justify compounding. [3] Ohio's Board of Pharmacy follows FDA guidance on this point.

503B Outsourcing Facilities

Section 503B outsourcing facilities produce larger, non-patient-specific batches and are FDA-registered. They may compound tesamorelin under 503B rules, and because 503B facilities operate under current Good Manufacturing Practice (cGMP) standards, their products carry a higher quality assurance baseline. [5] An Ohio prescriber may obtain tesamorelin from a 503B facility for office use or for dispensing directly to patients, provided state distribution requirements are met.

Gray-Area Warning

Any vendor selling tesamorelin without requiring a prescription, or marketing it as a "research chemical" rather than a pharmaceutical, is operating outside both federal and Ohio law. The FDA has issued warning letters to compounders producing bulk peptides in violation of 503A/503B standards. [6] Patients should confirm that any pharmacy filling their tesamorelin prescription is licensed by the Ohio State Board of Pharmacy and, if a compounder, registered under 503A or 503B as appropriate.

Clinical Profile: What Tesamorelin Does and Why It Is Prescribed

Understanding the clinical rationale strengthens the documentation that supports a lawful prescription. Tesamorelin is a synthetic 44-amino-acid GHRH analogue that binds pituitary GHRH receptors, stimulating pulsatile release of endogenous growth hormone (GH) and downstream IGF-1. This mechanism distinguishes it from recombinant human GH (rhGH) because it preserves the normal GH pulsatility axis.

Phase III Trial Data for Lipodystrophy

In the key Phase III trials published in the New England Journal of Medicine (Falutz et al., 2010, N=412), tesamorelin 2 mg/day subcutaneous injection reduced visceral adipose tissue (VAT) by a mean of 18% versus 3% in the placebo group at 26 weeks (P<0.001). [7] Triglycerides also fell by a mean of 50 mg/dL in the treatment group. Secondary endpoints showed improvement in the waist-to-hip ratio and patient-reported body image scores.

Off-Label Body-Composition Research

Outside the HIV context, smaller trials have examined tesamorelin for non-HIV lipodystrophy, age-related visceral adiposity, and metabolic syndrome. A 2019 randomized controlled trial (N=61, NCT02432170) published in Clinical Infectious Diseases found that tesamorelin reduced liver fat fraction in HIV-positive adults with non-alcoholic fatty liver disease (NAFLD) by 37% versus an increase of 7% in the placebo group (P<0.001). [8]

Cognitive Research

A separate line of research has examined tesamorelin's effect on cognition. A 2021 trial (Baker et al., N=152) published in Nature Communications found that tesamorelin improved verbal memory scores in older adults with mild cognitive impairment compared to placebo over 20 weeks, with effect sizes in the mild-to-moderate range. [9] This research is preliminary and off-label; it does not constitute FDA-approved evidence, but it does provide the clinical basis a prescriber could cite when documenting off-label medical necessity.

Standard Dosing and Monitoring

The FDA-approved dose is 2 mg subcutaneously once daily, injected into the abdomen. The prescriber should obtain a baseline IGF-1 level before initiating therapy and recheck at 3 months to assess response and titrate within the physiologic range. The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults notes that IGF-1 should be maintained within the age-adjusted normal range to minimize adverse effects, including insulin resistance and peripheral edema. [10] Contraindications include active malignancy, pregnancy, and hypersensitivity to tesamorelin or mannitol (a component of the lyophilized formulation).

How to Get a Legal Tesamorelin Prescription in Ohio

Obtaining tesamorelin legally in Ohio follows a straightforward medical pathway.

Step 1. Establish Care With a Qualified Prescriber

The prescriber must hold an active Ohio medical license (or a valid telehealth license recognized by Ohio). Endocrinologists, infectious-disease specialists, and hormone-focused primary-care or telehealth clinicians are the most common prescribers. The encounter, whether in-person or synchronous telehealth, must include a clinical history, physical exam or documented review of systems, relevant labs, and a documented treatment rationale.

Step 2. Obtain Baseline Laboratory Work

Before prescribing, clinicians routinely order:

• Fasting glucose and HbA1c (tesamorelin may modestly impair glucose tolerance)
• IGF-1 (age- and sex-adjusted reference range)
• Lipid panel (particularly triglycerides, given the cardiovascular context)
• HIV status if prescribing for the FDA-approved indication
• CBC and CMP as general baseline

Step 3. Choose a Licensed Pharmacy

Patients have three dispensing options:

1. Brand-name Egrifta SV from any licensed retail or specialty pharmacy with a valid prescription.
2. 503A compounded tesamorelin from an Ohio-licensed compounding pharmacy, provided the clinical differentiation criteria above are met.
3. 503B outsourcing facility product supplied through the prescribing clinic or a licensed distributor.

Prices for brand-name Egrifta SV may exceed $3,000 per month without insurance. Compounded tesamorelin from a licensed 503A or 503B facility typically costs $150 to $400 per month, though pricing varies by pharmacy and formulation. Insurance coverage for the brand is available through some HIV-specialty plans, with Theratechnologies offering a patient assistance program for qualifying patients.

Step 4. Follow Up and Document Ongoing Medical Necessity

Ohio's Medical Practice Act requires that prescribers document continued medical necessity for any ongoing prescription. A follow-up encounter every 3 to 6 months with repeat IGF-1 and fasting glucose is standard practice for patients on tesamorelin. If IGF-1 rises above the upper limit of the age-adjusted normal range, the dose should be reduced or discontinued, consistent with Endocrine Society guidance. [10]

Risks of Obtaining Tesamorelin Outside Legal Channels

Patients occasionally encounter online vendors selling tesamorelin vials labeled "for research use only." These products carry serious legal and safety risks.

From a legal standpoint, purchasing a prescription drug without a valid prescription violates both federal law (21 U.S.C. § 353) and Ohio law (ORC 4729.51). The FDA classifies unsolicited importation of unapproved drugs as a violation of the FD&C Act, regardless of personal-use intent. [11]

From a safety standpoint, products from unlicensed vendors have no cGMP oversight. Testing by independent laboratories has found that some peptide vials sold as "research chemicals" contain incorrect concentrations, bacterial endotoxins, or entirely different compounds. A patient injecting an impure product risks injection-site reactions, systemic infection, or endocrine disruption.

A prescriber who knowingly directs a patient to an unlicensed vendor could face Ohio Medical Board disciplinary action under ORC 4731.22.

Summary of the Legal Field

The table below consolidates the key regulatory touchpoints for tesamorelin in Ohio.

| Regulatory Layer | Status | Key Source | |---|---|---| | FDA approval | Approved (Egrifta SV, 2 mg/day) | FDA NDA 022505 | | DEA schedule | Not scheduled | 21 U.S.C. § 812 | | Ohio state restriction | None beyond federal | ORC Chapter 4729 | | 503A compounding | Permitted with clinical differentiation | FD&C Act § 503A | | 503B outsourcing | Permitted, cGMP required | FD&C Act § 503B | | Telehealth prescribing | Permitted under ORC 4743.09 | Ohio telehealth statute | | Research-use-only sales | Illegal for human use | 21 U.S.C. § 353 |